News & Views

News:

Upcoming Presentations:

Dr. Borgert will speak  on “Experimental Evaluation of Interactions: Pitfalls and Challenges”, at the 41st Annual Symposium, Society of Toxicology of Canada, Montreal, Quebec, Nov 29-Dec 1, 2009.   The theme of the  Symposium is  "Toxicology of Drug and Chemical Mixtures: From Mechanisms to Risk Assessment"

Dr. Borgert will speak at the upcoming Annual Meeting of the Society for Risk Analysis,  December 6-9, 2009, Baltimore, Maryland,  in the session, “Moving Past the Rhetoric: Meaningful Dialogue on the Issue of Funding and Scientific Integrity.”

Recent Presentations:

Dr. Borgert was faculty in a continuing education course, Current Approaches in Mixture Risk, at the Society of Toxicology, Continuing Education Program, 47th Annual Meeting, March 15-19, 2009, Baltimore, Maryland. Dr. Borgert presented a lecture on “Relative Potency Factors in Drug Safety Assessment.”

Borgert, CJ. National Academy of Sciences workshop on Characterizing the Potential Human Toxicity from Low Doses of Pharmaceuticals in Drinking Water: Are New Risk Assessment Methods or Approaches Required? Considerations for Single Chemical vs Mixture Risk Assessment December 11-12, 2008, Washington, D.C.

Other News:

Dr. Borgert was President of the International Society of Regulatory Toxicology and Pharmacology in 2007-2008, and he currently serves on the Society’s Governing Council. He was the Society’s Treasurer 2003-2006.

Endocrine Disruption Issue & Involvement:

Dr. Borgert served on the U.S.EPA Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) as the general representative for Small Business stakeholders. EDSTAC was a Federal Advisory Committee to the U.S.EPA commissioned to develop recommendations for screening pesticides, industrial and agricultural chemicals pursuant to requirements of the 1996 Food Quality Protection Act and 1996 Amendments to the Safe Drinking Water Act.  In addition to serving on the plenary committee, he also served on the Screening and Testing Workgroup of the EDSTAC and Co-chaired the Communication and Outreach Workgroup.  He drafted a considerable section of the EDSTAC report on validation of the screening and testing batteries.

In 1998, APT developed detailed protocols for the EDSTAC-recommended assays and used them to conduct a cost estimate survey that is published in Appendix S of the EDSTAC Final Report.  The survey, including complete protocols, is in the Federal Docket for the EDSTAC. APT updated the survey in 2003.

Dr. Borgert continues to participate in inter-industry groups addressing the validation and standardization of endocrine screening and testing assays pursuant to EDSTAC, and in 2002, served on the OECD Peer-Review Panel for Validation of the Uterotrophic Assay.

At the 2006 Chemical Producers and Distributors Association (CPDA) meeting, Dr. Borgert presented his perspectives on the status of the Endocrine Disruptor Screening Program (EDSP), including Validation of Tier 1 Screens and Tier 2 Tests, and Priority Setting of pesticide ingredients for initial screening.  This presentation was followed by an interview published in the Pesticide.net Insider eJournal Volume 3,
Issue 5.